Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase 2 study with Baker's Antifol in solid tumors.

V Rodriguez, S P Richman, R S Benjamin

    Cancer Research
    |April 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    The african organization for research and training in cancer.

    Current oncology (Toronto, Ont.)·2012
    Same author

    A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    Leukemia·2012
    Same author

    The road to cancer control goes through leukemia research.

    Current oncology (Toronto, Ont.)·2009
    Same author

    Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

    Leukemia·2009
    Same author

    Lesson on leukemia.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007

    Baker's Antifol showed limited efficacy in advanced cancers, with a 10% response rate. However, it demonstrated activity in specific cancers like renal cell carcinoma and lung adenocarcinoma, with manageable toxicities.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Baker's Antifol is an investigational chemotherapeutic agent.
    • Advanced cancers present significant treatment challenges.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of Baker's Antifol in adult patients with advanced cancers.
    • To identify specific cancer types that may respond to Baker's Antifol therapy.

    Main Methods:

    • A phase II clinical trial involving 138 adult patients with advanced cancers.
    • Patients were treated with Baker's Antifol.
    • Response rates and toxicities were assessed.

    Main Results:

    • The overall complete response + partial response rate was 10%.
    • Notable responses were observed in lung adenocarcinoma (13%), colorectal carcinoma (16%), and renal cell carcinoma (50%).

    Related Experiment Videos

  • Dermatitis incidence decreased with a 3-day administration schedule, and toxicities included stomatitis, gastrointestinal symptoms, and mild myelosuppression.

    • Conclusions:

    • Baker's Antifol exhibits modest antitumor activity in advanced cancers.
    • Further investigation, including combination therapy studies, is warranted for Baker's Antifol.